Vaccines and Biodefense

When you see “Get Your Flu Vaccine Here” signs and banners outside pharmacies and in doctor’s offices, you might think, “isn’t it too late for that?” The answer is no.

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

New vaccines employing biotech innovations are changing the way we prevent illness.

Youve probably heard the term pandemic a lot in the news today. What you might not know is that biotechnology researchers are working to create new vaccination options to help stop the next big pandemic before it starts.

Are biotech drugs really that different from traditional pharmaceuticals.  You bet they are.  Learn why here.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

Biotechnology, the combination of biology and technology, includes biologic applications, diagnostic tools and businesses that improve everyday life by providing solutions to some of life's most vexing problems.

What happens in Washington influences biotechnology progress every bit as much as what happens on Wall Street or in the lab.

Thirty six thousand Americans die from seasonal flu each year, now there is additional threat a possible global avian flu pandemic.

Has a member of your family been vaccinated against hepatitis B? Do you know someone who has diabetes? Has anyone in your family had heart disease?

Letters, Testimony & Comments

July 1 2015
On June 15, 2015, the Department of Defense's (DoD's) Joint Project Manager-Medical Countermeasure Systems (JPM-MCS) held a co-located Industry Day in conjunction with the BIO Convention in Philadelphia, Pennsylvania. The MCS Industry Day focused on industry feedback related to the DoD's proposed use of an Other Transaction Authority (OTA) contracting mechanism. 
March 7 2014
On March 7, 2014, BIO submitted comments to the U.S. Office of Personnel Management (OPM) regarding OPM’s February 4, 2014 Multi-State Plan (MSP) Program Call Letter. BIO’s comments address the critical nature of the Affordable Care Act’s immunization coverage standard.
February 25 2014
BIO joined with the American Pharmacists Association (APhA), Association of State and Territorial Health Officials (ASTHO), Immunization Action Coalition (IAC), Merck, and the National Association of County and City Health Officials (NACCHO) to submit comments to the Centers for Medicare and Medicaid Services (CMS) regarding the February 4, 2014 Draft Letter to Issuers in the Federally-facilitated Marketplaces. 
December 19 2013
BIO submitted comments on the Centers for Medicare and Medicaid Services' (CMS’s) Federally Qualified Health Center (FQHC) Prospective Payment System (PPS) proposed rule, specifically as it relates to vaccine coverage for Medicare beneficiaries and reimbursement for vaccines under Medicare Part B.
July 10 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.

Press Releases

April 29 2015
Washington, D.C. (April 29, 2015) – The Biotechnology Industry Organization (BIO) today releases the following statement on the 21st Century Cures Initiative discussion draft shared by Chairman Fred Upton (R-MI), Rep. Diana DeGette (D-CO), Rep. Frank Pallone, Jr. (D-NJ), Rep. Joe Pitts (R-PA), and Rep. Gene Green (D-TX). 
February 6 2015
Bill would encourage vaccine research and benefit public health Washington, D.C. (February 6, 2015) – The Biotechnology Industry Organization (BIO) applauds the introduction of the Vaccine Access, Certainty, and Innovation Act of 2015. Sponsored by Representatives Renee Ellmers (R-NC) and G.K. Butterfield (D-NC), the Act is expected to be an important part of the Energy & Commerce Committee’s 21st Century Cures Initiative and would modernize the discovery, development, and delivery of vaccines. 
December 9 2014
Washington, D.C. (December 9, 2014) – The Biotechnology Industry Organization (BIO) applauds today’s declaration by Health and Human Services Secretary Sylvia M. Burwell under the Public Readiness and Emergency Preparedness (PREP) Act which will help advance the development and availability of experimental Ebola vaccines. The declaration provides immunity under U.S. law against legal claims related to the manufacturing, testing, development, distribution and administration of three experimental Ebola vaccines.
December 4 2014
Washington, D.C. (December 4, 2014) – Today marks the inaugural meeting of the Blue Ribbon Study Panel on Biodefense, a bipartisan panel co-chaired by former Senator Joe Lieberman and former Governor and Homeland Security Secretary Tom Ridge. Panelists former Senator Tom Daschle, former Secretary of Health and Human Services Donna Shalala, former US Homeland Security Advisor Kenneth Wainstein, and Biotechnology Industry Organization (BIO) President and CEO and former Representative Jim Greenwood. The study will be directed by Dr. Robert Kadlec, former special assistant to the President for homeland security and senior director for biological defense policy in the White House Homeland Security Council.
June 20 2013
BIO applauds Sens. Max Baucus (D-MT) and Orrin Hatch (R-UT) and Reps. Jim Gerlach (R-PA) and Richard Neal (D-MA) on the passage of H.R. 475 to update the existing excise tax to cover the newest seasonal influenza vaccines.